Loading...

PE/Cyanine7 anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1dot5_PECy7_030206
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE/Cyanine7 (filled histogram) or rat IgG2b, κ PE/Cyanine7 isotype control (open histogram).
  • GK1dot5_PECy7_030206
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) PE/Cyanine7 (filled histogram) or rat IgG2b, κ PE/Cyanine7 isotype control (open histogram).
See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100421 25 µg $88
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100422 100 µg $215
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  2. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  3. Prüss H, et al. 2017. Nat Neurosci. 10.1038/nn.4643. PubMed
  4. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  5. Draijer C, et al. 2018. Sci Rep. 8:5105. PubMed
  6. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  7. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  8. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  9. Le TM et al. 2018. Journal of neurochemistry. 145(2):139-153 . PubMed
  10. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
  11. Proietti M, et al. 2019. Nat Commun. 10:250. PubMed
  12. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  13. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  14. Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed
  15. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  16. Wang H, et al. 2019. Nat Commun. 10:1898. PubMed
  17. Li C, et al. 2018. Cell. 174:285. PubMed
  18. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
  19. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  20. Perruzza L, et al. 2019. Sci Rep. 9:9315. PubMed
  21. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
  22. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  23. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  24. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  25. Kaufmann U et al. 2019. Cell metabolism. 29(5):1104-1118 . PubMed
  26. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
  27. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  28. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  29. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
  30. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  31. Godwin MS, et al. 2019. JCI Insight. 4:e126070. PubMed
  32. Groves HT, et al. 2020. MBio. 11:e03236-19. PubMed
  33. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
  34. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  35. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
  36. Nakornpakdee Y, et al. 2018. Asian Pac J Allergy Immunol. 36:265. PubMed
  37. Nagamata S, et al. 2019. Sci Rep. 9:3911. PubMed
  38. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
  39. Wang W, et al. 2020. Immunity. 51(6):1102-1118.e7.. PubMed
  40. Chen M, et al. 2019. Cell Stem Cell. 25:501. PubMed
  41. Crespo ÂC, et al. 2020. Cell. 182(5):1125-1139. PubMed
  42. Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed
  43. Zhou G, et al. 2019. FASEB J. 33:11396. PubMed
  44. Ambrosino E, et al. 2006. Cancer Res . 66:7734. PubMed
  45. Rolla S, et al. 2010. J Immunol. 184:6124. PubMed
  46. Ohmichi Y, et al. 2011. J Exp Med . 208:1015. PubMed
  47. Lee P, et al. 2014. J Immunol. 192:178. PubMed
  48. Sanders K, et al. 2015. Cancer Immunol Res. 3: 891-901. PubMed
  49. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
  50. XS R, et al. 2015. Diabetes. 64 90. PubMed
  51. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  52. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  53. O'Brien S, Zhang M 2015. J Immunol. 195: 695-705. PubMed
  54. Kondo M, et al. 2016. J Immunol. 196: 563 - 572. PubMed
  55. Akhter N, et al. 2016. J Biol Chem. 291: 23672 - 23680. PubMed
  56. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  57. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  58. Gogoi H, et al. 2020. Front Immunol. 1.620833333. PubMed
  59. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
  60. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  61. Busse DC, et al. 2020. J Virol. 94:00:00. PubMed
  62. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  63. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  64. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  65. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  66. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  67. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
  68. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  69. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  70. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  71. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  72. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  73. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  74. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
  75. Li C, et al. 2021. Cell Metabolism. 33(8):1610-1623.e5. PubMed
  76. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  77. Wang W, et al. 2021. STAR Protocols. 2(3):100756. PubMed
  78. Lim CX, et al. 2020. Cell Rep. 3793:30. PubMed
  79. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
  80. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  81. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  82. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  83. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
  84. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  85. Yu Z, et al. 2021. Biomed Res Int. 2021:9958745. PubMed
  86. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  87. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  88. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
  89. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  90. Kimura S, et al. 2020. Am J Transplant. 20:977. PubMed
  91. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
  92. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  93. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  94. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  95. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  96. An J, et al. 2022. iScience. 25:103570. PubMed
  97. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  98. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  99. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  100. Schönberger K, et al. 2022. STAR Protoc. 3:101408. PubMed
  101. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  102. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  103. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  104. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
  105. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  106. Kelley WJ, et al. 2022. JCI Insight. 7: . PubMed
  107. Ma YV, et al. 2021. MAbs. 13:2003281. PubMed
  108. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  109. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  110. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  111. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  112. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  113. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  114. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
  115. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  116. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  117. Kitajima Y, et al. 2022. Cells. 11:. PubMed
  118. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  119. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  120. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  121. Godwin MS, et al. 2021. Am J Physiol Lung Cell Mol Physiol. 320:L393. PubMed
  122. Kojima H, et al. 2021. Scand J Immunol. 93:e13020. PubMed
  123. Simula L, et al. 2022. Mol Oncol. 16:188. PubMed
  124. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  125. Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
  126. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  127. Diao L, et al. 2022. iScience. 25:105511. PubMed
  128. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
  129. Collin R, et al. 2020. J Immunol. 205:133. PubMed
  130. Alam A, et al. 2022. Cancer Cell. 40:153. PubMed
  131. Xiong T, et al. 2022. Cancer Sci. 113:1955. PubMed
  132. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  133. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  134. del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed
  135. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  136. Kang IH, et al. 2022. iScience. 25:104818. PubMed
  137. Mansouri S, et al. 2022. J Immunol. 209:2114. PubMed
  138. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  139. Roy S, et al. 2022. Am J Cancer Res. 12:4977. PubMed
  140. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  141. Kulkarni R, et al. 2023. Life Sci Alliance. 6: . PubMed
  142. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  143. Zhao K, et al. 2023. Front Immunol. 14:1101769. PubMed
  144. Novaj A, et al. 2023. Int J Mol Sci. 24: . PubMed
  145. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  146. Kodali S, et al. 2022. J Immunol. 208:1085. PubMed
  147. Meacham CE, et al. 2022. Nat Cell Biol. 24:697. PubMed
  148. Sanmarco LM, et al. 2022. Nature. 611:801. PubMed
  149. Wang X, et al. 2023. J Immunother Cancer. 11:. PubMed
  150. Rege SV, et al. 2023. Commun Biol. 6:292. PubMed
  151. Saha S, et al. 2023. Sci Rep. 13:4609. PubMed
  152. del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed
  153. Tang M, et al. 2023. Sci Adv. 9:eade6624. PubMed
RRID
AB_312706 (BioLegend Cat. No. 100421)
AB_312707 (BioLegend Cat. No. 100422)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account